



Any Correlation Between Prostate Volume and Incidence of Prostate Cancer: A Review of Reported Data for the Last Thirty Years

Justine R Yamashiro 
Werner TW de Riese 

Department of Urology, School of
Medicine, Texas Tech University Health
Sciences Center, Lubbock, TX, USA

Purpose: Prostate cancer (PCa) is the most common non-skin cancer in men worldwide and more than 80% of men with PCa also have histo-anatomical findings of benign prostate hyperplasia (BPH). It is well documented that BPH develops in the transition zone (TZ), whereas 80–85% of PCa originates in the peripheral zone (PZ) of the prostate. Possible causal links between both disease entities are controversially discussed in the current literature. Some studies have reported that larger prostates have a decreased incidence of PCa compared to smaller prostates. The purpose of this systematic review is to comprehensively summarize studies analyzing any association between prostate gland volume and incidence of PCa.

Methods: A thorough literature review was performed between 01.01.1990 through 02.28.2020 using PubMed and applying the “PRISMA” guidelines. Inclusion and exclusion criteria were defined.

Results: Our systematic review found 41 articles reporting an inverse (negative) relationship between prostate gland volume and incidence of prostate cancer. Sample sizes ranged from 114 to 6692 patients in these single institutional and multi-institutional studies. Thirty-nine (95%) of the 41 articles showed a statistically significant inverse relationship. In our search, no study was found showing a positive correlation between BPH size and the incidence of PCa.

Conclusion: To our knowledge, this is the first systematic review on the important clinical question of interaction between prostate size and the incidence of PCa. The results are demonstrating an inverse relationship, and therefore reveal strong evidence that large prostates may be protective of PCa when compared to smaller prostates.

Keywords: prostate size, benign prostate hyperplasia, inverse relationship

Introduction

Prostate cancer (PCa) is the most common non-skin cancer in men worldwide. Despite recent progress in diagnosing and treatment of PCa, there are still 1,600,000 cases and 366,000 deaths annually in the United States.¹ It is well documented in the literature that 80–85% of PCa arises from the peripheral zone of the prostate gland, and metastatic PCa is the third-leading cause of cancer-related death.²

More than 80% of men with PCa also have histological findings of benign prostate hyperplasia (BPH) with or without clinical symptoms.² Both disease entities occur in the same age group (elderly males), have hormone-dependent growth, and respond to antiandrogen therapy.^{3,4} Some clinicians support the

Correspondence: Werner TW de Riese
Department of Urology, School of
Medicine, Texas Tech University Health
Sciences Center, 3601 - 4th Street STOP
7260, Lubbock, TX, 79430, USA
Tel +1 806-743-3862
Fax +1 806-743-3030
Email werner.deriese@ttuhsc.edu

controversial narrative that BPH is the precursor for PCa.⁵ But other clinicians state that diagnostics and treatment of symptomatic BPH may increase the chance of diagnosing an incidental prostate cancer, and some reports state that large BPH prostates may be even protective against PCa.^{3,5,6} Some recent studies have reported that larger prostates have a decreased incidence of PCa compared to smaller prostates, but there are no review papers analyzing any relationship across multiple institutions and studies. The purpose of this report is to provide a systematic review, and therefore more insight regarding any association between BPH (prostate gland) volume and the incidence of PCa.

Materials and Methods

A focused literature search was conducted on the PubMed database according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.⁷ The predefined search terms “prostate cancer” AND “prostate volume” AND “prostate size” were used to identify articles describing any relationship between prostate gland volume and incidence of PCa. The inclusion criteria for the search were as follows: a) articles in English, b) published in the years between January 1st, 1990 through December 31st, 2020, c) cohort studies only in humans, d) data provided for prostate volumes and e) incidence of biopsy proven prostate cancer in the reported cohort. The exclusion criteria were as follows: a) articles not published in English, b) studies not in humans, c) no detailed data on prostate volume provided in relation to the incidence of biopsy proven prostate cancer in the cohort, and d) biopsies in patients after previous treatment for PCa. The extracted data variables were as follows: authors, journal, year of publication, sample size of reported cohort, association between prostate volume and incidence of biopsy-proven PCa, and p-value to assess statistical significance.

The p-value of the statistical analysis results were taken from the respective studies, no additional statistics were performed on the extrapolated data as these listed studies were all peer-reviewed. These p-values were placed on a forest plot to graphically compare the significance of each of the studies' results using Excel (version 2108).

Results

The literature search identified 41 original articles meeting the inclusion criteria for review. Figure 1 illustrates the search strategy and study selection flowchart according to the PRISMA guidelines.⁷ Table 1 and Figure 2 present the

clinically relevant findings from each study. The studies ranged from a sample size of 114 to 6692 patients. There was a mix of single institutional and multi-institutional studies. For instance, Al-Azab et al assessed prostate volumes of 1796 patients using transrectal ultrasound (TRUS) and concluded that “men with a large prostate volume (larger than 72cc) had a 20.5% risk of prostate cancer on biopsies compared to men with the smallest prostate volume (less than 38cc) who had 65.8% risk of cancer” (p-value <0.001).⁸ Karakiewicz et al reported, in a sample size of 1974 patients, the highest positive biopsy rate (39.6%) among prostates smaller than 20cc, whereas the lowest positive biopsy rate (10.1%) was found in glands between 80–90cc (p-value <0.02).⁹

Thirty-nine of the forty-one articles (95%) showed a statistically significant inverse (negative) relationship between prostate size and the incidence of PCa with a p-value of at least <0.05 (Table 1), and the Forest plot of all studies (Figure 2) showed a significance level of 0.01. In the PRISMA-guided search no study was found showing a positive correlation between these two clinical parameters.

Discussion

The inverse relationship between prostate size and the incidence and aggressiveness of PCa has been demonstrated in numerous clinical studies as listed in Table 1. As prostate volume increases, incidence of PCa decreases and patients with larger prostates have also been shown to have a better prognosis.¹⁰ These findings are rarely challenged in the recent literature and no study in our systematic review demonstrated a positive correlation between prostate volume and incidence of PCa. Al-Khalil et al demonstrated that the incidence of PCa was reduced by 40% in larger prostates with a volume >65cc when compared to smaller prostates with a volume <35cc (p-value <0.05). The study also showed that out of 110 biopsy-positive patients with prostates <35cc, 10 patients had a Gleason score of ≥ 8 (9.1%) and out of 27 biopsy-positive patients with prostates >65cc, only 1 had a Gleason score of ≥ 8 (3.7%).¹⁰

The zones of the prostate gland are divided into the central zone (CZ), transition zone (TZ), peripheral zone (PZ), and anterior fibromuscular stroma. These zones arise from different embryologic origins and are distinguished by their appearance, anatomic landmarks, biologic functions, and susceptibility to pathology (for details see Table 2).¹¹ In imaging, TRUS and on MRI, only the PZ




Figure 1 PRISMA flowchart for literature search and selection of studies.

Notes: *Literature search range was from January 1990–December 2020: “prostate cancer” AND “prostate volume” AND “prostate size”. **Records excluded by PubMed automated filter system. Adapted from Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health-care interventions: explanation and elaboration. *PLoS MED*. 2009;6(7):e1000100⁷.

can be well differentiated from the “rest” of the prostate, which is often referred to as the “central gland” by radiologist. The term “central gland” must be distinguished from the term “central zone” which is difficult to isolate on imaging.

It is well documented in anatomical and imaging studies that BPH originates in the TZ while 80–85% of PCa originates in the PZ.^{11,12} A recent review article summarized that the “histo-anatomical changes within the peripheral zone caused by BPH growth lead to significant tissue transformation within the peripheral zone”.¹² This transformation causes thickening of the prostatic capsule secondary to fibrosis which is also called the surgical capsule by urologists due to the distinctive plane between the TZ

and PZ in large BPH prostates which is much less evident in small prostates. This process causes epithelial cell atrophy within the PZ due to direct pressure-related tissue injury and reduced blood flow caused by the expanding TZ in growing BPH. Due to this process, gland atrophy is seen within the PZ. As 80% of PCa originates from the glandular epithelium within the PZ this supports the hypothesis that these dynamic interactions between the growing TZ and compressed PZ explain the decreased incidence of PCa in large BPH prostates.^{13,14} Sellers et al performed multiparametric MRI prostate studies on biopsy naïve patients. This study focused on specific PZ measurements which demonstrated compression of the PZ in large prostates compared to smaller prostates: Small and mid-

Table I List of Studies and Relationship Between Prostate Size and Incidence of Prostate Cancer, Respectively

Author et al.	Journal	Year	# of Pts (n)	Inverse Correlation Prostate Size and Prostate Cancer (Yes/ No/Ambiguous)	p-value ^a
Al-Khalil ⁶	Int Urol Nephrol	2016	448	Yes	<0.05
Al-Khalil ¹⁰	Res Rep Urol	2016	448	Yes	<0.001
Chang ³¹	Oncotarget	2017	247	Yes	<0.0001
Zheng ³²	PLOS One	2019	422	Yes	<0.001
Briganti ³³	Eur J Cancer	2007	3412	Yes	<0.001
Newton ³⁴	J Urol	2009	2880	Yes	<0.001
Nepal ³⁵	Turk J Uro	2020	659	Yes	<0.001
Sooriakumaran ³⁶	Urol Int	2011	2207	Yes	<0.001
Yoon ³⁷	Urol J	2011	474	Yes	<0.05
Fang ³⁸	Biomed Res Int	2015	345	Yes	<0.001
Yadav ³⁹	J Endourol	2009	700	Yes	0.001
Al-Azab ⁸	J Urol	2007	1796	Yes	<0.001
Elliot ²⁰	Clin Cancer Res	2009	1304	Yes	<0.001
Haas ⁴⁰	Urol Int	2017	148	Yes	0.004
Colleselli ⁴¹	BJU Int	2007	345	Yes	<0.05
Sfakianos ⁴²	BJU Int	2010	3040	Yes	0.01
Novara ⁴³	BJU Int	2009	143	Yes	0.002
Ung ⁴⁴	J Urol	2003	750	Yes	0.0074
Kobayashi ⁴⁵	Int J Urol	2005	154	Yes	<0.0001
Uzzo ⁴⁶	Urology	1995	1021	Yes	<0.01
Hong ⁴⁷	Urology	2014	1756	Yes	0.032
Rundle ⁴⁸	Prostate	2017	6692	Yes	^b
Wu ⁴⁹	Asian J Androl	2014	1486	Yes	<0.05
Porcaro ⁵⁰	Urol Int	2015	251	Yes	<0.0001
Porcaro ⁵¹	Urol Int	2017	596	Yes	<0.0001
Fowke ⁵²	Cancer Causes Control	2007	286	Yes	<0.01
Eskicorapci ⁵³	J Urol	2005	503	Yes	<0.001
Werahera ⁵⁴	Int J Clin Exp Pathol	2012	114	Yes	^b
Bruno ⁵⁵	J Urol	2007	296	Yes	<0.001
Kulkarni ⁵⁶	J Urol	2006	369	Yes	0.008
Karakiewicz ⁹	Urology	1997	1974	Yes	<0.001
Mir ⁵⁷	BJU Int	2008	390	Yes	0.001
Kim ⁵⁸	Yonsei Med J	2013	1035	Yes	<0.001
Ankerst ⁵⁹	J Urol	2013	1094	Yes	<0.0001
Tanaka ⁶⁰	Hinyokika Kyo	2007	210	Yes	<0.001
Tang ⁶¹	Asian J Androl	2013	261	Yes	<0.001
Aganovic ⁶²	Med Arh	2012	323	Yes	<0.05
Kwon ⁶³	BJU Int	2010	579	Yes	0.025
Gohji ⁶⁴	Cancer	1997	287	Yes	0.0009
Egawa ⁶⁵	Int J Urol	1999	706	Yes	<0.0001
Rietbergen ⁶⁶	Urology	1998	1202	Yes	<0.0001

Notes: ^aP-values calculated by each study, respectively. ^bStudies did not provide p-value.

size prostates had a huge range of PZ thickness whereas large prostates with a total volume around 90 mL or above showed a noticeable drop in PZ thickness suggesting the PZ can resist pressure from the TZ growth to a certain point only.¹⁵

This inverse relationship may also explain the results of the Prostate Cancer Prevention Trial, where almost 19,000 patients received continuous Finasteride medication. The treatment arm showed a more than a twofold increase in high grade aggressive PCa. Finasteride is




Figure 2 Forest plot for p-value of reviewed studies.

known to affect and reduce the growth of the TZ, thus giving the glandular epithelium of the PZ more room within the prostate to grow and expand.¹⁶ This clinical observation has been confirmed by Lorenzo et al in mathematical simulation studies analyzing the controversial effects of 5 α reductase inhibitors (SARIs), and found that “the shrinkage of the prostate induced by SARIs reduced

the hydrostatic stress that had accumulated over years of BPH in prostatic tissue, which led to a mechanical state that favored the development of PCa”.¹⁷

Many studies listed in Table 1 have reported that prostate volume is one of the most significant predictive factors for the detection of prostate cancer both in univariate and multivariate analysis. Historically, prostate-specific

Table 2 Summary of Histologic Composition and Embryologic Origins of the Different Zones of the Prostate Gland

	Central Zone (CZ)	Transition Zone (TZ)	Peripheral Zone (PZ)
Volume of normal prostate (%)	25	5	70
Embryologic origin	Wolffian duct	Urogenital sinus	Urogenital sinus
Origin of prostatic adenocarcinoma (%)	5	10–15	80–85
Benign prostatic hyperplasia (%)	–	100	–

antigen (PSA) alone has not proven to be a good diagnostic tool in detecting PCa but combining or adjusting it with gland volume, prostate-specific antigen density (PSAD), has improved its diagnostic value.^{18,19} Elliott et al demonstrated that PSA performance was significantly better in men with smaller prostates at detecting both low-grade and high-grade PCa.²⁰ Al-Azab et al suggested that a smaller prostate volume may be the strongest predictor of cancer detection in the PSA range of 2.0 to 9.0 ng/mL, and that adjusting for the patient's prostate volume may help with earlier detection and decrease the need for repeated prostate biopsies.⁸ Previous studies have shown the amount of BPH, and not cancer, is the major factor responsible for the elevation of PSA. However, elevated PSA is the reason for many patients with large prostates to undergo biopsies which are often unnecessary and only lead to overdiagnosis and subsequent overtreatment.²¹ PSAD performance in detecting PCa is affected by prostate volume. The predictive value of PSAD in detecting PCa is higher in small- and medium-sized prostates compared to larger glands. Therefore, many clinical researchers and investigators have recommended that clinicians should counsel patients with large prostates and elevated PSA to consider conservative management such as sequential PSA measurements and not to proceed with biopsies.^{22,23}

As outlined in this systemic review, many recent, statistically significant and powerful studies are confirming that BPH may be protective against prostatic cancer supporting the proposed mathematical model by Lorenzo et al that growth of the TZ due to BPH causes increased hydrostatic pressure and compresses the PZ (where 80–85% of PCa originates). As mentioned earlier, this histo-anatomical process leads to fibrosis and glandular atrophy of the PZ, and thus likely lowers the risk of clinically significant PCa.²⁴ This hypothesis is well illustrated by the histo-anatomical study of Guzman et al in showing a decrease in gland density and increase in tissue fibrosis within the PZ in larger prostates when compared to smaller prostates (see Figure 3A and B).²⁵

We are aware of some limitations as this systematic review includes a relatively small number of articles that met the inclusion criteria. Furthermore, the selected studies, although statistically significant, carried large heterogeneity. When reviewing the histo-anatomical studies, the anatomical reconstruction of the prostate by histological specimen slides can be challenging. Gross examination techniques vary greatly among pathologists, with some using coronal cuts, while others use sagittal or transverse

cuts, leading to differences in the orientation of the different portions of the prostate specimen. Due to the nature of the prostate, localizing the precise boundaries between the different zones by imaging can be challenging and operator-dependent (ie, TRUS). This is much less an issue with MRI. Another limitation is the variability in biopsy protocol. Sextant and extended needle biopsies have been shown to yield different diagnostic power. Some studies have suggested increasing the number of biopsies for larger prostates may improve the detection of PCa. However, studies have proven that past a certain gland




Figure 3 H&E-stained slides of different sized prostate specimens at 50× magnification: **(A)** Small Prostate Specimen (24 g). The external, posterior margin is inked and marked with an asterisk*. A decent number of hyperplastic glands (as indicated by arrows) are present and easily visible in the peripheral zone (PZ) close to the thin capsule (black line). Reproduced with permission from Dove Medical Press Limited, Guzman JA, Sharma P, Smith LA et al. Histological changes of the peripheral zone in small and large prostates and possible clinical implications. *Res Rep Urol.* 2019;11:77–81.²⁵ **(B)** Large Prostate Specimen (100 g). The external, posterior margin is also inked and marked with an asterisk*. The arrow is indicating an atrophic gland within the extended fibrotic layer/ surgical capsule (black line). This capsule is much thicker in comparison to Figure 2A, and no hyperplastic glands are present. Reproduced with permission from Dove Medical Press Limited, Guzman JA, Sharma P, Smith LA et al. Histological changes of the peripheral zone in small and large prostates and possible clinical implications. *Res Rep Urol.* 2019;11:77–81.²⁵

volume the detection rate of PCa differs minimally between number of biopsies.^{26,27} Furthermore, most of the studies listed in our review were cross-sectional and observational studies which can cause bias in different categories and are difficult to further investigate. Therefore, additional bias assessment on these individual studies were not performed. In this context publication bias should also be mentioned as our review was limited to the PubMed database and the expertise of the authors involved.

Even when considering the limitations mentioned above, this systematic review of clinical studies within the last 30 years strongly supports the hypothesis of protective benefits of BPH against development and progression of clinically significant PCa. With increased use of multiparametric MRI of the prostate in the diagnostic and management of PCa, future studies will likely further elucidate this relationship, in particular because MRI/Ultrasound Fusion biopsies allow increased precision in the diagnosis of clinically significant PCa.^{28,29} This will likely decrease the problem of sampling error experienced with systematic TRUS prostatic biopsy that tends to be more prevalent in larger (BPH associated) prostates.³⁰ As MRI technology and its use in the diagnosis of PCa becomes more accessible, future studies will rectify and decrease the impact of sampling error bias associated with this hypothesis. If the described disease process of BPH-induced atrophy of the PZ glandular tissue and its subsequent protective potential against PCa is confirmed through future research and studies, it will have important clinical implications related to the diagnosis and treatment of BPH and PCa.

Conclusion

This systematic review using the PRISMA guidelines studies the association of BPH (prostate) size and the incidence of PCa. Ninety-five percent (39/41) of the reviewed clinical studies show an inverse correlation between these two clinical parameters. Thus, there is increased evidence supporting the hypothesis that BPH size may be protective of PCa. This review and the outlined discussion should encourage further studies in exploring the relationship between prostate volume and incidence and aggressiveness of PCa to better understand this phenomenon. If the outlined hypothesis of the dynamic interactions between the different prostatic zones in a growing prostate is correct, it will have relevant clinical implications on future diagnosis and treatment of BPH and PCa.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Wang G, Zhao D, Spring DJ, et al. Genetics and biology of prostate cancer. *Genes Dev.* 2018;32(17–18):1105–1140. doi:10.1101/gad.315739.118
2. Liu FC, Hua KC, Lin JR, et al. Prostate resected weight and post-operative prostate cancer incidence after transurethral resection of the prostate. *Medicine (Baltimore).* 2019;98(3):e13897. doi:10.1097/MD.00000000000013897
3. Guess HA. Benign prostatic hyperplasia and prostate cancer. *Epidemiol Rev.* 2001;23:152–158. doi:10.1093/oxfordjournals.epirev.a000782
4. Bostwick DG, Cooner WH, Denis L, et al. The association of benign prostatic hyperplasia and cancer of the prostate. *Cancer.* 1992;70(1 Suppl):291–301.
5. Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. *Nat Rev Urol.* 2013;10(1):49–54. doi:10.1038/nrurol.2012.192
6. Al-Khalil S, Boothe D, Durdin T, et al. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective date review. *Int Urol Nephrol.* 2016;48(1):91–97. doi:10.1007/s11255-015-1146-2
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100
8. Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. *Urology.* 2007;69(1):103–107. doi:10.1016/j.urol.2006.09.041
9. Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. *Urology.* 1997;49(1):55–59. doi:10.1016/S0090-4295(96)00360-3
10. Al-Khalil S, Ibilbor C, Cammack JT, et al. Association of prostate volume with incidence and aggressiveness of prostate cancer. *Res Rep Urol.* 2016;8:201–205.
11. Bhavsar A, Verma S. Anatomic imaging of the prostate. *Biomed Res Int.* 2014;2014:728539. doi:10.1155/2014/728539
12. Holder K, Galvan B, Sakya J, et al. Anatomical changes of the peripheral zone depending on benign prostatic hyperplasia size and their potential clinical implications: a review for clinicians. *Urol Pract.* 2021;8(2):259–263. doi:10.1097/UPJ.0000000000000201
13. Weaver PE, Smith LA, Sharma P, et al. Quantitative measurements of prostate capsule and gland density and their correlation to prostate size: possible clinical implications in prostate cancer. *Int Urol Nephrol.* 2020;52(10):1829–1837. doi:10.1007/s11255-020-02527-6
14. Marks LS, Roehrborn CG, Wolford E, et al. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. *J Urol.* 2007;177(4):1408–1413. doi:10.1016/j.juro.2006.11.095
15. Sellers J, Wagstaff RG, Helo N, et al. Quantitative measurements of prostatic zones by MRI and their dependence on prostate size: possible clinical implications in prostate cancer. *Ther Adv Urol.* 2021;13:1–9. doi:10.1177/17562872211000852
16. Tarle M, Spajic B, Kraljic I, et al. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendocrine differentiation and aggressive prostate cancer. *Anticancer Res.* 2009;29(5):1797–1801.

17. Lorenzo G, Hughes TJR, Realì A, et al. A numerical simulation study of the dual role of 5 α -reductase inhibitors on tumor growth in prostates enlarged by benign prostatic hyperplasia via stress relaxation and apoptosis upregulation. *Comput Methods Appl Mech Eng*. 2020;362:112843. doi:10.1016/j.cma.2020.112843
18. Dunn MW. Prostate Cancer Screening. *Semin Oncol Nurs*. 2017;33(2):156–164. doi:10.1016/j.soncn.2017.02.003
19. Yu HJ, Lai MK. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer. *Urology*. 1998;51(5):125–130. doi:10.1016/S0090-4295(98)00066-1
20. Elliott CS, Shinghal R, Presti JC. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes. *Clin Cancer Res*. 2009;15(14):4694–4699. doi:10.1158/1078-0432.CCR-08-2277
21. Alberts AR, Schoots IG, Roobol MJ. Prostate-specific antigen-based prostate cancer screening: past and future. *Int J Urol*. 2015;22(6):524–532. doi:10.1111/iju.12750
22. Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume. *Prostate*. 2020;80(16):1444–1449. doi:10.1002/pros.24078
23. Yusim I, Krenawi M, Mazor E, et al. The use of prostate specific antigen density to predict clinically significant prostate cancer. *Sci Rep*. 2020;10(1):20015. doi:10.1038/s41598-020-76786-9
24. Lorenzo G, Hughes TJR, Dominguez-Frojan P, et al. Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth. *Proc Natl Acad Sci U S A*. 2019;116(4):1152–1161. doi:10.1073/pnas.1815735116
25. Guzman JA, Sharma P, Smith LA, et al. Histological changes of the peripheral zone in small and large prostates and possible clinical implications. *Res Rep Urol*. 2019;11:77–81.
26. Chen Y, Jiang X, Liu R, et al. The specific choice of transrectal ultrasound-guided prostate biopsy scheme based on prostate specific antigen and prostate specific antigen density. *Med Sci Monit*. 2019;25:6230–6235. doi:10.12659/MSM.915826
27. Inahara M, Suzuki H, Kojima S, et al. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. *Urology*. 2006;68(4):815–819. doi:10.1016/j.urology.2006.05.010
28. Pepe P, Garufi A, Priolo GD, et al. Multiparametric MRI/TRUS fusion prostate biopsy: advantages of a transperineal approach. *Anticancer Res*. 2017;37(6):3291–3294.
29. Das CJ, Razik A, Sharma S, et al. Prostate biopsy: when and how to perform. *Clin Radiol*. 2019;74(11):853–864. doi:10.1016/j.crad.2019.03.016
30. Schoenfeld L, Jones JS, Zippe CD, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. *BJU Int*. 2007;99(4):770–774. doi:10.1111/j.1464-410X.2006.06728.x
31. Chang Y, Chen R, Yang Q, et al. Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality. *Oncotarget*. 2017;8(21):34836–34843. doi:10.18632/oncotarget.16753
32. Zheng S, Jiang S, Chen Z, et al. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer. *PLoS One*. 2019;14(11):e0218645. doi:10.1371/journal.pone.0218645
33. Briganti A, Chun FK, Suardi N, et al. Prostate volume and adverse prostate cancer features: fact not artifact. *Eur J Cancer*. 2007;43(18):2669–2677. doi:10.1016/j.ejca.2007.09.022
34. Newton MR, Phillips S, Chang SS, et al. Smaller prostate size predicts high grade prostate cancer at final pathology. *J Urol*. 2010;184(3):930–937. doi:10.1016/j.juro.2010.04.082
35. Nepal SP, Nakasato T, Ogawa Y, et al. Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. *Turk J Urol*. 2020;46(6):449–454. doi:10.5152/tud.2020.20248
36. Sooriakumaran P, Srivastava A, Bhagat D, et al. Prostate volume and its correlation with histopathological outcomes in prostate cancer. *Urol Int*. 2011;86(2):152–155. doi:10.1159/000322361
37. Yoon BI, Shin TS, Cho HJ, et al. Is it effective to perform two more prostate biopsies according to prostate-specific antigen level and prostate volume in detecting prostate cancer? Prospective study of 10-core and 12-core prostate biopsy. *Urol J*. 2012;9(2):491–497.
38. Fang D, Ren D, Zhao C, et al. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL who underwent TRUS-guided prostate biopsy: the utilization of PAMM score. *Biomed Res Int*. 2015;2015:596797. doi:10.1155/2015/596797
39. Yadav R, Tu JJ, Jhaveri J, et al. Prostate volume and the incidence of extraprostatic extension: is there a relation? *J Endourol*. 2009;23(3):383–386. doi:10.1089/end.2008.0247
40. Haas M, Günzel K, Miller K, et al. Is the ellipsoid formula the new standard for 3-tesla MRI prostate volume calculation without endorectal coil? *Urol Int*. 2017;98(1):49–53. doi:10.1159/000448593
41. Colleselli D, Bektic J, Schaefer G, et al. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy. *BJU Int*. 2007;100(6):1264–1267. doi:10.1111/j.1464-410X.2007.07174.x
42. Sfakianos JP, Thorner DA, Dovirak O, et al. Optimizing prostate cancer detection during biopsy by standardizing the amount of tissue examined per core. *BJU Int*. 2011;108(10):1578–1581. doi:10.1111/j.1464-410X.2011.10239.x
43. Novara G, Boscolo-Berto R, Lamon C, et al. Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate. *BJU Int*. 2010;105(9):1242–1246. doi:10.1111/j.1464-410X.2009.08954.x
44. Ung JO, San Francisco IF, Regan MM, et al. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. *J Urol*. 2003;169(1):130–135. doi:10.1016/S0022-5347(05)64052-9
45. Kobayashi T, Mitsumori K, Kawahara T, et al. Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0–10.0 ng/mL. *Int J Urol*. 2005;12(11):969–975. doi:10.1111/j.1442-2042.2005.01189.x
46. Uzzo RG, Wei JT, Waldbaum RS, et al. The influence of prostate size on cancer detection. *Urology*. 1995;46(6):831–836. doi:10.1016/S0090-4295(99)80353-7
47. Hong SK, Poon BY, Sjöberg DD, et al. Prostate size and adverse pathologic features in men undergoing radical prostatectomy. *Urology*. 2014;84(1):153–157. doi:10.1016/j.urology.2014.04.006
48. Rundle A, Wang Y, Sadasivan S, et al. Larger men have larger prostates: detection bias in epidemiologic studies of obesity and prostate cancer risk. *Prostate*. 2017;77(9):949–954. doi:10.1002/pros.23350
49. Wu YS, Na R, Xu JF, et al. The influence of prostate volume on cancer detection in the Chinese population. *Asian J Androl*. 2014;16(3):482–486. doi:10.4103/1008-682X.125905
50. Porcaro AB, Novella G, Molinari A, et al. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. *Urol Int*. 2015;94(3):270–285. doi:10.1159/000362176
51. Porcaro AB, Novella G, Cacciamani G, et al. Prostate volume index associates with a decreased risk of prostate cancer: results of a large cohort of patients elected to a first biopsy set. *Urol Int*. 2017;98(1):22–27. doi:10.1159/000447432
52. Fowke JH, Motley SS, Wills M, et al. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. *Cancer Causes Control*. 2007;18(4):375–384. doi:10.1007/s10552-007-0119-x

53. Eskicorapci SY, Guliyev F, Akdogan B, et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. *J Urol*. 2005;173(5):1536–1540. doi:10.1097/01.ju.0000154242.60413.3d
54. Werahera PN, Sullivan K, La Rosa FG, et al. Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. *Int J Clin Exp Pathol*. 2012;5(9):892–899.
55. Bruno JJ, Armenakas NA, Fracchia JA. Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/mL. *J Urol*. 2007;177(5):1741–1744. doi:10.1016/j.juro.2007.01.067
56. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. *J Urol*. 2006;175(2):505–509. doi:10.1016/S0022-5347(05)00236-3
57. Mir MC, Planas J, Raventos CX, et al. Is there a relationship between prostate volume and Gleason score? *BJU Int*. 2008;102(5):563–565. doi:10.1111/j.1464-410X.2008.07696.x
58. Kim YM, Park S, Kim J, et al. Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen. *Yonsei Med J*. 2013;54(5):1202–1206. doi:10.3349/ymj.2013.54.5.1202
59. Ankerst DP, Till C, Boeck A, et al. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. *J Urol*. 2013;190(1):70–76. doi:10.1016/j.juro.2012.12.108
60. Tanaka N, Fujimoto K, Yoshikawa M, et al. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. *Hinyokika Kyo*. 2007;53(7):459–465.
61. Tang P, Jin XL, Uhlman M, et al. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10–50 ng mL⁻¹. *Asian J Androl*. 2013;15(3):409–412. doi:10.1038/aja.2013.11
62. Aganovic D, Prcic A, Kulovac B, et al. Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. *Med Arh*. 2012;66(1):41–44. doi:10.5455/medarh.2012.66.41-44
63. Kwon T, Jeong IG, You D, et al. Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level? *BJU Int*. 2010;106(5):633–638. doi:10.1111/j.1464-410X.2009.09182.x
64. Gohji K, Nomi M, Egawa S, et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. *Cancer*. 1997;79(10):1969–1976. doi:10.1002/(SICI)1097-0142(19970515)79:10<1969::AID-CNCR19>3.0.CO;2-T
65. Egawa S, Suyama K, Takashima R, et al. Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters. *Int J Urol*. 1999;6(10):493–501. doi:10.1046/j.1442-2042.1999.00098.x
66. Rietbergen JB, Kranse R, Hoedemaeker RF, et al. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. *Urology*. 1998;52(2):237–246. doi:10.1016/S0090-4295(98)00138-1

Research and Reports in Urology

Publish your work in this journal

Research and Reports in Urology is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease; Investigation and

treatment of urological disease; Pharmacology of drugs used for the treatment of urological disease. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/research-and-reports-in-urology-journal>

Dovepress